CN1616074A - 灵芝孢子油脂肪乳剂 - Google Patents
灵芝孢子油脂肪乳剂 Download PDFInfo
- Publication number
- CN1616074A CN1616074A CN 200410051661 CN200410051661A CN1616074A CN 1616074 A CN1616074 A CN 1616074A CN 200410051661 CN200410051661 CN 200410051661 CN 200410051661 A CN200410051661 A CN 200410051661A CN 1616074 A CN1616074 A CN 1616074A
- Authority
- CN
- China
- Prior art keywords
- ganoderma spore
- spore oil
- oil
- medicine
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 66
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 9
- 239000003921 oil Substances 0.000 claims abstract description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000007924 injection Substances 0.000 claims abstract description 23
- 238000002347 injection Methods 0.000 claims abstract description 23
- 239000010685 fatty oil Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 7
- 235000019198 oils Nutrition 0.000 claims description 67
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 235000010445 lecithin Nutrition 0.000 claims description 13
- 229940067606 lecithin Drugs 0.000 claims description 13
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 235000005687 corn oil Nutrition 0.000 claims description 9
- 239000007951 isotonicity adjuster Substances 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 210000004681 ovum Anatomy 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 26
- 229940090044 injection Drugs 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 150000003648 triterpenes Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000006268 Sarcoma 180 Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 238000011046 pyrogen test Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
油相 | 乳化剂 | 等渗剂 | 抗氧剂 | |
实施例3 | 孢子油2g、大豆油3g | 硬脂酸甘油酯0.1g | 甘露醇6.0g | 维生素E 10mg |
实施例4 | 孢子油4g、长链脂肪油6g | 卵磷脂0.8g、普流罗尼F682.0g | 甘油2.3g | 焦亚硫酸钠50mg |
实施例5 | 孢子油2g、中链脂肪油8g | 普流罗尼F683.0g | 葡萄糖3.0g | 维生素E 10mg维生素A 20mg |
实施例6 | 孢子油6g、大豆油12g | 卵磷脂1.8g | 山梨醇5.0g | 无 |
实施例7 | 孢子油8g、大豆油18g | 伯洛沙姆38810g | 甘油0.5g | 维生素C1000mg |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100516613A CN100348205C (zh) | 2004-09-29 | 2004-09-29 | 灵芝孢子油脂肪乳剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100516613A CN100348205C (zh) | 2004-09-29 | 2004-09-29 | 灵芝孢子油脂肪乳剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1616074A true CN1616074A (zh) | 2005-05-18 |
CN100348205C CN100348205C (zh) | 2007-11-14 |
Family
ID=34764040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100516613A Expired - Lifetime CN100348205C (zh) | 2004-09-29 | 2004-09-29 | 灵芝孢子油脂肪乳剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100348205C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009105912A1 (zh) * | 2008-02-26 | 2009-09-03 | 广州汉方现代中药研究开发有限公司 | 一种灵芝孢子油脂肪乳剂及其质量控制方法与应用 |
CN1990032B (zh) * | 2005-12-31 | 2011-03-23 | 天津天士力制药股份有限公司 | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 |
CN101601695B (zh) * | 2009-06-26 | 2012-02-29 | 江苏省中医药研究院 | 灵芝三萜提取物的自微乳化纳米组合物及其制备方法 |
CN106692213A (zh) * | 2016-12-23 | 2017-05-24 | 广州白云山汉方现代药业有限公司 | 一种灵芝孢子油、灵芝孢子油脂肪乳和应用 |
CN114028279A (zh) * | 2021-10-26 | 2022-02-11 | 上海应用技术大学 | 一种灵芝自乳化油脂发酵液、发酵方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255519C (zh) * | 2003-06-20 | 2006-05-10 | 陈列 | 灵芝孢子油萃取和精制方法 |
-
2004
- 2004-09-29 CN CNB2004100516613A patent/CN100348205C/zh not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1990032B (zh) * | 2005-12-31 | 2011-03-23 | 天津天士力制药股份有限公司 | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 |
WO2009105912A1 (zh) * | 2008-02-26 | 2009-09-03 | 广州汉方现代中药研究开发有限公司 | 一种灵芝孢子油脂肪乳剂及其质量控制方法与应用 |
DE112008003744T5 (de) | 2008-02-26 | 2011-04-14 | Guangzhou Hanfang Natural Medicine Research & Development Co., Ltd., Guangzhou | Fettemulsion, umfassend Ganoderma-Sporenöl, Verfahren zur Qualitätskontrolle und Verwendung davon |
CN101601695B (zh) * | 2009-06-26 | 2012-02-29 | 江苏省中医药研究院 | 灵芝三萜提取物的自微乳化纳米组合物及其制备方法 |
CN106692213A (zh) * | 2016-12-23 | 2017-05-24 | 广州白云山汉方现代药业有限公司 | 一种灵芝孢子油、灵芝孢子油脂肪乳和应用 |
CN114028279A (zh) * | 2021-10-26 | 2022-02-11 | 上海应用技术大学 | 一种灵芝自乳化油脂发酵液、发酵方法和应用 |
CN114028279B (zh) * | 2021-10-26 | 2023-10-27 | 杭州慧农生物科技有限公司 | 一种灵芝自乳化油脂发酵液、发酵方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100348205C (zh) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1301666C (zh) | 一种能增强免疫力的保健食品及其制备方法 | |
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN1709248A (zh) | 一种兰索拉唑冻干粉针剂及其制备方法 | |
CN1887270A (zh) | 一种盐酸黄连素纳米乳制剂及其制备方法 | |
CN1813868A (zh) | 一种治疗和改善慢性疲劳综合症的组合物及其制备方法 | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
CN106389329B (zh) | 一种双嘧达莫口服乳剂给药系统及其制备方法 | |
CN1616074A (zh) | 灵芝孢子油脂肪乳剂 | |
CN106135906A (zh) | 吉林人参低聚肽在制备抗疲劳的食品或保健食品中的用途 | |
CN1709236A (zh) | 一种含有多西他赛的脂肪乳剂及其制备方法 | |
CN102895186A (zh) | 注射用青蒿琥酯脂肪乳的制备及其在疟疾治疗中的应用 | |
CN102258467B (zh) | 静脉注射用缓释青蒿素及其衍生物脂肪乳的配方及制备 | |
CN1698588A (zh) | 异丙酚口服麻醉药及其制备方法 | |
CN106389477B (zh) | 一种土生戈登氏菌的全细胞植物油提取物的制备方法和应用 | |
CN1720948A (zh) | 红茴香滴丸及其制备方法 | |
CN1973826A (zh) | 含有依托泊苷的脂质微球注射液及其制备方法 | |
CN1772020A (zh) | 毛冬青冻干粉针剂及其制备方法 | |
CN1225242C (zh) | 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法 | |
CN1296089C (zh) | 一种莪术注射制剂及其制备方法 | |
CN1107501C (zh) | 阿苯达唑乳剂 | |
CN1602855A (zh) | 连翘苷在制备治疗肥胖病口服药物和保健食品中的应用 | |
CN1278676C (zh) | 姜黄素注射制剂及其制备方法 | |
CN1771909A (zh) | 一种青蒿素脂肪乳剂及其制备方法与应用 | |
CN1504191A (zh) | 葫芦素脂质体组方及其制剂 | |
CN1857255A (zh) | 一种注射用银杏内酯b乳剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU HANFANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HANFANG MODEM CHINESE TRADITIONAL MEDICINE RESEARCH DEVELOPMENT CO., LTD., GUANG |
|
CP01 | Change in the name or title of a patent holder |
Address after: 510240 Haizhuqu District Jiangnan Road, Guangdong, No. 134, No. Patentee after: GUANGZHOU HANFANG PHARMACEUTICAL Co.,Ltd. Address before: 510240 Haizhuqu District Jiangnan Road, Guangdong, No. 134, No. Patentee before: Guangzhou Hanfang modern Chinese medicine research and Development Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20071114 |